Therapeutics News and Research

RSS

Scientists identify new cellular mechanism underlying hydronephrosis

One of the most common congenital defects in humans - it is detected in approximately 0.5% of fetuses analyzed by routine antenatal sonography - is a kidney abnormality known as hydronephrosis. Hydronephrosis arises because the flow of urine from the kidney to the bladder is impeded.

21 Feb 2011

Researchers receive $2 million NIH grant to identify biomarkers in children with hemangiomas

A nearly $2 million grant from the National Institutes of Health will help investigators at Nationwide Children's Hospital search for biomarkers that may be linked to the development and outcome of hemangiomas, the most common soft tissue tumor in children.

21 Feb 2011

How Huntington's disease proteins move from cell to cell

One bad apple is all it takes to spoil the barrel. And one misfolded protein may be all that's necessary to corrupt other proteins, forming large aggregations linked to several incurable neurodegenerative diseases such as Huntington's, Parkinson's and Alzheimer's.

19 Feb 2011

Researchers identify CD19-L protein that facilitates recognition, destruction of leukemia cells

Scientists at the Children's Center for Cancer and Blood Diseases and The Saban Research Institute of Children's Hospital Los Angeles today announced a breakthrough discovery in understanding how the body fights leukemia.

18 Feb 2011

Chelsea prices underwritten public offering of 8.75 million shares of common stock

Chelsea Therapeutics International, Ltd. announced today that it has priced a public offering of 8.75 million shares of its common stock at a price of $4.00 per share which will result in gross proceeds of $35 million.

18 Feb 2011

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

BioMimetic Therapeutics, today announced highlights from its analyst and investor meeting which was held on Thursday, February 17 in San Diego, CA in conjunction with the American Academy of Orthopedic Surgery Annual Meeting.

18 Feb 2011

TI Pharma launches new research project on stem cell transplant

Top Institute Pharma is today launching a new research project that should make stem cell transplants more successful. A stem cell transplant is usually performed on adults with acute leukemia.

18 Feb 2011

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Cell Therapeutics, Inc. today announced that it has entered into a securities purchase agreement to sell, subject to certain closing conditions, securities in a registered offering to a single life sciences institutional investor. The Company may use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products.

18 Feb 2011

Intrinsic initiates enrollment in Barricaid device clinical trial

Intrinsic Therapeutics, Inc., a developer of novel lumbar spine anulus closure devices, announced today that it has enrolled the first patient, December 17, 2010, in a Randomized Clinical Trial of its Barricaid device.

18 Feb 2011

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

miRagen Therapeutics, Inc., a privately-held biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's compound MGN-4893 for the treatment of polycythemia vera, a myeloproliferative disease characterized by an overabundance of blood cells and platelets in the body.

18 Feb 2011

Benitec strengthens patent position in RNAi

Benitec Limited (ASX: BLT), (PINK:BNIKF), a world leader in expressed gene silencing for human therapeutics, is pleased to announce that the United States Patent and Trademark Office (USPTO) has today indicated that it is issuing the Re-examination Certificate, the formal final step in the USPTO’s confirmation of patentability of claims in the key ‘099 Graham Patent [US Patent No. 6,573,099] "Genetic Constructs for Delaying or Repressing the Expression of a Target Gene", the wide-ranging platform technology patent covering the use of expressed RNA interference (RNAi) in human therapeutic applications.

17 Feb 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

New method may eliminate colonoscopies

Nobody enjoys colonoscopies, including mice. University of Missouri researchers are excited about the potential of using genetic biomarkers to predict colon cancer caused by inflammation. A new method developed at the MU Research Animal Diagnostic Laboratory (RADIL) could eventually lead to a method that might eliminate colonoscopies altogether.

17 Feb 2011

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

Amicus Therapeutics today announced that additional positive data from the ongoing Phase 2 extension study of its investigational drug Amigal™ (migalastat HCl) for Fabry disease will be presented at the Lysosomal Disease Network WORLD Symposium in Las Vegas, Nevada, February 16-18th, 2011.

17 Feb 2011

New fully human monoclonal antibodies to battle Chikungunya

The Singapore Immunology Network (SIgN), an institute of the Agency of Science, Technology and Research (A*STAR), and VIVALIS, a French biopharmaceutical company, announced today the discovery of two new fully human monoclonal antibodies which could battle Chikungunya, a disease that currently has no available vaccine or specific treatment.

16 Feb 2011

Study explores role of proline containing peptides in inhibiting anti-apoptotic function of XIAP

Basic and translational research on cancer, and development of new cancer therapeutics, has focused on different aspects of cancer cellular function. One area of focus is the life and death of a cancer cell. Apoptosis, also known as programmed cell death, is a fundamental process of cells including cancer cells. The signal transduction pathways of apoptosis involve many different proteins and their interactions with each other.

16 Feb 2011

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Mentor Capital, Inc. reports that Advaxis, Inc. has been added as the newest member of the Mentor Capital Cancer Immunotherapy Index.

16 Feb 2011

Novel molecular approach using biomarker can predict colorectal cancer staging, recurrence

A quantitative, molecular analysis of lymph nodes in patients deemed colorectal cancer-free was found to be an effective predictor of recurrence, according to a study from researchers at the Kimmel Cancer Center at Jefferson and published online Feb 9. in Clinical Cancer Research.

16 Feb 2011

CTI's fourth quarter net loss increases to $34.1 million

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the fourth quarter and year ended December 31, 2010.

16 Feb 2011

AMT 2010 total net income increases to EUR 1.4 million

Amsterdam Molecular Therapeutics, a leader in the field of human gene therapy, today reported its results for the year to December 31, 2010.

16 Feb 2011

Therapeutics News and Research

Scientists identify new cellular mechanism underlying hydronephrosis

Researchers receive $2 million NIH grant to identify biomarkers in children with hemangiomas

How Huntington's disease proteins move from cell to cell

Researchers identify CD19-L protein that facilitates recognition, destruction of leukemia cells

Chelsea prices underwritten public offering of 8.75 million shares of common stock

BioMimetic highlights updates on orthopedic and rehabilitation devices during AAOS meeting

TI Pharma launches new research project on stem cell transplant

Cell Therapeutics enters securities purchase agreement with single life sciences institutional investor

Intrinsic initiates enrollment in Barricaid device clinical trial

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

Benitec strengthens patent position in RNAi

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

New method may eliminate colonoscopies

Amicus to present additional positive data from Amigal Phase 2 extension study for Fabry disease

New fully human monoclonal antibodies to battle Chikungunya

Study explores role of proline containing peptides in inhibiting anti-apoptotic function of XIAP

Advaxis added to Mentor Capital Cancer Immunotherapy Index

Novel molecular approach using biomarker can predict colorectal cancer staging, recurrence

CTI's fourth quarter net loss increases to $34.1 million

AMT 2010 total net income increases to EUR 1.4 million

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Latest News